Live
- Run for men’s health issues on Nov 23, 24
- Quick commerce workforce expansion to surge by 60 pc in India
- State on the brink of a public uprising over Waqf issue, says BJP
- Dr Soumya Swaminathan to talk on TB, COVID at UoH on Nov 25
- Darshan has not followed interim bail guidelines, Govt tells HC
- Parties keenly await bypoll results, spotlight on high-profile Channapatna
- 22 Central Medicine Stores to come up in TG in a week: Min Damodar Rajanarsimha
- Exit poll predictions will be proven wrong, says Dy CM
- Consumption of ganja rocks National Sanskrit University
- Air India institute to create skilled engineers for aircraft maintenance
Dr. Reddy's launch Propofol Injectable Emulsion in US market
Pharma major Dr Reddys Laboratories Ltd on Thursday announced the launch of Propofol Injectable Emulsion, USP, in the US market
Hyderabad: Pharma major Dr. Reddy's Laboratories Ltd on Thursday announced the launch of Propofol Injectable Emulsion, USP, in the US market.
It's a therapeutic equivalent generic version of Diprivan (propofol) Injectable Emulsion, USP, approved by the US Food and Drug Administration (USFDA), the company said in a statement.
Dr. Reddy's Propofol Injectable Emulsion, USP, is available in 10 mg/mL vials for single patient use only.
The Hyderabad-based firm also made it clear that it will not accept orders from correctional facilities and prison systems whose intended use of the product is to aid in lethal injection. It said it required the same commitment from wholesalers and distributors.
Dr. Reddy's said it was committed to providing affordable and innovative medicines for healthier lives. It neither condones nor supports the off-label use or misuse of its drugs.
"In the strongest possible terms, Dr. Reddy's objects to the use of any of its products to facilitate or otherwise aid lethal injections. Consistent with this position, Dr. Reddy's uses distribution controls to market Propofol Injectable Emulsion, USP."
The Diprivan brand and generic had US sales of approximately $310 million MAT for the most recent twelve months ending in November 2018, according to IMS Health.
